FDA approves new treatment for a type of late-stage lung cancerFormulary staffFormulary Enews
MIT cancer biologists have identified a new therapeutic target for small cell lung cancer, an especially aggressive form of lung cancer with limited options for treatment. Lungcanceris the leading cause of cancer-associated mortality in the United States and worldwide, with a five-year survival rat...
The work being carried out by Combes and his colleagues offers new hope. They are working to improve the delivery to cells of so-called therapeutic mRNA as a treatment for lungcancer. This method is a more targeted and effective treatment approach. You have probably heard that mRNA technology ...
Estelamari Rodriguez and Rogerio C. LilenbaumClinical Lung CancerRodriguez E, Lilenbaum RC. New treatment strategies in patients with advanced non-small-cell lung cancer and per- formance status 2. Clin Lung Cancer. 2008;9:326-330.
immunotherapy is a well-known treatment strategy for cancer that can enhance the existing anti-tumor response so that immune cells can restrict the growth of malignant cells. Again, immunotherapy can effectively target the cancer cells while causing minimal adverse effects [2,3]. Moreover, to prov...
The drug therapy for non-small cell lung cancer (NSCLC) have always been issues of poisonous side effect, acquired drug resistance and narrow applicable population. In this study, we built a novel network analysis method (difference- correlation- enrichm
Antiviral Medications for Treatment of Nonsevere InfluenzaA Systematic Review and Network Meta-Analysis Ya Gao, PhD; Yunli Zhao, MD; Ming Liu, PhD; et al. Abstract Full Text JAMA Intern Med. Published online January 13, 2025. doi:10.1001/jamainternmed.2024.7193 This systematic review and...
There have been major advances in the immunotherapy of cancer in recent years, including the development of T cell engagers — antibodies engineered to redirect T cells to recognize and kill cancer cells — for the treatment of haematological malignancies. However, the field still faces several chal...
Approximately 10-15% of patients with NSCLC haveEGFRmutations. While treatment with EGFR TKIs is effective at killing most cancer cells, a small number of drug-tolerant cells persist. These cells can remain dormant, even invisible, for long periods of time, but they eventually grow and metastasi...
A new inhalable dry powder treatment for lung cancer shows a significant increase in survival rates and is far less invasive than current treatment options, which frequently include radiation and surgery. This research is being presented at the 2010 Inte